CSL
OrganizationHeard in 14 episodes across 5 shows since Aug 2026
CSL is a global biotechnology company headquartered in Australia. Through CSL Behring, CSL Seqirus, and CSL Vifor, it develops and manufactures plasma-derived and recombinant therapies, vaccines, and medicines for serious and chronic diseases.
Episodes
This week
Expert statements
Share of the conversation
Mentions of CSL per 1,000 mentions of anything, 7-day rolling, across the podcasts PodLume Trends follows.
Show the data
| Day | Share (7-day) | Mentions |
|---|---|---|
| Aug 6 | 0.11‰ | 1 |
| Aug 12 | 0.07‰ | 1 |
| Aug 18 | 0.06‰ | 1 |
| Aug 19 | 0.07‰ | 1 |
| Aug 23 | 0.14‰ | 2 |
| Aug 24 | 0.18‰ | 1 |
| Aug 26 | 0.14‰ | 1 |
| Sep 2 | 0.06‰ | 2 |
| Sep 16 | 0.03‰ | 1 |
| Sep 17 | 0.06‰ | 1 |
| Sep 18 | 0.17‰ | 4 |
| Sep 20 | 0.19‰ | 1 |
| Oct 5 | 0.03‰ | 1 |
What experts have said about CSL
8 statements · 7 positive · 1 negative
CSL is an industry-leading business in blood plasma and vaccines.
“It's a wonderful business, blood plasma vaccines, all that sort of stuff. It's an industry leader.”
Open the episode · Rates rise around the world, why the Aged Pension isn't enough & Pimp my Portfolio with Owen RaskListen at 31:42
CSL was sufficiently underpriced to justify maximum portfolio exposure and subsequently rallied sharply.
“We were maximum CSL across all our funds. And since then, it's had this astonishing rally.”
Open the episode · Riding the rebound in CSL, Cochlear and finding the next opportunityListen at 14:00
CSL shares rose 38% in one month after its reporting result.
“the stock just, you know, it was up 38% in a month.”
Open the episode · Hofflin: Big moves are creating great value on the ASXListen at 14:14
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
14 episodes featuring CSL, newest first
- Oct 5, 2026
Australia’s policy bets collide with markets, technology and growthThe Contrarians with Adam and AdirOct 5, 2026 - Sep 20, 2026
Australia’s retirement assumptions meet a tougher investing realityEquity Mates Investing PodcastSep 20, 2026 - Sep 18, 2026
Volatility widens Australia’s value-investing gapThe Rules of InvestingSep 18, 2026 - Sep 18, 2026
Value investors find opportunity in Australia’s fallen angelsThe Rules of InvestingSep 18, 2026 - Sep 17, 2026
Management metrics can hide the real cost of growthStock TakeSep 17, 2026 - Sep 16, 2026
AI risks, oil shocks and the superannuation decisions that matterEquity Mates Investing PodcastSep 16, 2026